TOXICOLOGICAL SCIENCES, published by Oxford University Press, is a premier journal in the field of toxicology that has been a cornerstone of scientific discourse since its inception in 1981. With an impressive 2023 impact factor and ranked in the Q1 category for Toxicology, this journal is highly regarded among researchers, professionals, and students dedicated to pharmacology and toxicology. The journal is committed to advancing the understanding of toxicological science, covering a breadth of topics that include the mechanisms of toxicity, risk assessment, and the regulatory aspects affecting public health. With an ISSN of 1096-6080 and an E-ISSN of 1096-0929, TOXICOLOGICAL SCIENCES facilitates open access scholarly work, ensuring that critical research reaches a global audience and promotes collaborative learning. As it converges towards 2024, the journal remains pivotal in shaping the future of toxicology research, providing insights that are essential for developing safer chemicals and protecting environmental health.

The European Journal of Pharmaceutical Sciences is a prestigious academic journal dedicated to advancing the field of pharmaceutical science. Published by Elsevier, the journal boasts an impressive impact factor and is categorized in the Q1 quartile for pharmaceutical science as of 2023, signifying its influence and reputation within the academic community. With a Scopus ranking of #20 out of 183 in the fields of pharmacology, toxicology, and pharmaceutics, the journal provides a vital platform for researchers and practitioners to disseminate innovative studies and groundbreaking research that push the boundaries of drug development and delivery. Based in the Netherlands and operating since 1993, the journal seeks to cover a broad scope of topics related to pharmaceutical sciences, encouraging rigorous evaluations and discussions that enhance the understanding and application of this critical field. The absence of open access underscores the commitment to maintaining high scholarly standards, while still offering avenues for libraries and institutions to provide access to cutting-edge research. As the journal converges towards its 2024 milestones, it continuously aims to foster a vibrant exchange of knowledge among its diverse readership, comprising committed researchers, professionals, and students.

CLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.

CURRENT DRUG METABOLISM, published by Bentham Science Publishers Ltd, serves as a pivotal resource in the fields of Clinical Biochemistry and Pharmacology. With an ISSN of 1389-2002 and an E-ISSN of 1875-5453, this journal has carved a niche since its inception in 2000, offering in-depth research and reviews that bridge the gap between drug metabolism and its clinical applications. The journal finds itself positioned in the third quartile (Q3) for both Clinical Biochemistry and Pharmacology as of 2023, reflecting its significance within these scientific sectors, with Scopus rankings showcasing its role in advancing knowledge—rank #167 in Pharmacology and #66 in Clinical Biochemistry. Researchers and industry professionals are encouraged to contribute their findings, fostering a diverse platform that informs and inspires innovations in drug development and safety. While CURRENT DRUG METABOLISM operates under a traditional subscription model without open access, its rigorous peer-review process ensures the quality and integrity of the published work, making it indispensable for anyone engaged in drug research and biochemistry.

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.